Neurocrine Biosciences shared data from Phase 3 study of valbenazine for DCP; CP affects 3 per 1,000 children in US.
Biopharmaceutical company Neurocrine Biosciences Inc. (NASDAQ: NBIX) released data from its Phase 3 KINECT-DCP study investigating valbenazine's effectiveness, safety, and tolerability in individuals with dyskinetic cerebral palsy (DCP). Cerebral palsy (CP) is a nonprogressive condition affecting movement and posture, with an incidence rate of about three per 1,000 children in the U.S. Dyskinetic cerebral palsy (DCP) manifests in individuals with mixed hyperkinetic movements, such as dystonia and choreoathetosis, resulting in significant motor limitations. Neurocrine's Depression Drug did not meet Phase 2 goals but exhibited a promising safety profile. For more details, refer to the full story on Benzinga.com.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments